CSU-T 54.21 ATD-T 0.77 BN-T -1.13 ATH-T 0.14 ARX-T 1.08 NVA-T 0.4 CGRE-T 0.3
Daily Stock Opinions and Ratings
Stockchase Opinions

John Sinkins, CFA Oncolytics Biotech ONC-T WEAK BUY Jun 02, 2003

Biotechs have had good moves. Has a ways to go before their drug is on the market. Speculative in the short term.
John Sinkins, CFAJohn Sinkins, CFA
Unknown
Unlock Rating
$4.000

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

WEAK BUY

Oncolytics Biotech(ONC-T)

May 06, 2003
Interesting technology. Trials are turning out well, but too small a sampling at this time. Speculative.
Peter HodsonPeter Hodson
Unknown
Unlock Rating
$2.550

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

Oncolytics Biotech(ONC-T)

Jul 10, 2003
A wild stock. Created a virus that could reduce cancer dramatically. Long term potential could be good. Trials have only been small ones. Risky.
Peter HodsonPeter Hodson
Unknown
Unlock Rating
$3.250

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Oncolytics Biotech(ONC-T)

Sep 09, 2003
If they can find the right deals and get through the clinical trials, the upside would be phenomenal. Very volatile right now.
Peter HodsonPeter Hodson
Unknown
Unlock Rating
$3.490

Stock price when the opinion was issued

biotechnology pharmaceutical
WAIT

Oncolytics Biotech(ONC-T)

Jul 08, 2004
Has a pretty high beta, so the stock goes up and down like a yo-yo. Likes with the company is doing. At some point, a major pharmaceutical company will get interested in their technology. Would like to see more trials and results.
Peter HodsonPeter Hodson
No
Unlock Rating
$7.150

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

Oncolytics Biotech(ONC-T)

Sep 24, 2004
Not aware of any upcoming short term catalysts. Continuing with their trials. Never had bad results. Very volatile and still early stage.
Peter HodsonPeter Hodson
No
Unlock Rating
$7.250

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Oncolytics Biotech(ONC-T)

Feb 19, 2007
Phase 2 cancer company with some pretty decent results. They are a long way away from where they want to be. Product has huge potential.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.410

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Oncolytics Biotech(ONC-T)

Aug 08, 2018

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Jeff Parent B. Eng. FCSI CIMJeff Parent B. Eng. FCSI CIM
No
Unlock Rating
$5.490

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

STN-T -0.63$120.47
WSP-T 0.11$249.11
GWO-T 0.53$52.65
BCE-T 0.32$29.99
BIP.UN… -0.34$39.55
Advertising

Today's Top Picks

CSU-T 54.21$4718.46
ATD-T 0.77$70.38
BN-T -1.13$67.7
ATH-T 0.14$4.74
ARX-T 1.08$26.83

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

ATRL-T 0.55$69.52
AC-T 0.05$14.02
ENGH-T 0.29$24.81
QSR-T -0.8$86.37
BAC-N -0.66$37.33

Most Recent Experts

Chris Blumas

at Raymond James Investment Counsel Ltd.

Eric Nuttall

Ninepoint Partners

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

David Burrows

Barometer Capital Management

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Advertising
Advertising
© Stockchase Inc.